NASDAQ:CTKB Cytek Biosciences (CTKB) Stock Price, News & Analysis $6.11 -0.21 (-3.39%) Closing price 03:58 PM EasternExtended Trading$6.14 +0.03 (+0.47%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Cytek Biosciences Stock (NASDAQ:CTKB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cytek Biosciences alerts:Sign Up Key Stats Today's Range$5.99▼$6.3950-Day Range$4.61▼$6.3252-Week Range$3.31▼$6.39Volume1.34 million shsAverage Volume1.10 million shsMarket Capitalization$798.54 millionP/E RatioN/ADividend YieldN/APrice Target$5.67Consensus RatingHold Company Overview Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research. The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments. Headquartered in Fremont, California, Cytek serves customers in North America and international markets, including Europe and Asia, through a combination of direct sales and distribution partners. Its business builds on decades of experience in developing cell analysis technologies.AI Generated. May Contain Errors. Read More Cytek Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks32nd Percentile Overall ScoreCTKB MarketRank™: 1.607778690765 of 5 starsCytek Biosciences scored higher than 32% of companies evaluated by MarketBeat, and ranked 718th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingHold Consensus RatingCytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Downside RiskCytek Biosciences has a consensus price target of $5.67, representing about 7.5% downside from its current price of $6.13.Amount of Analyst CoverageCytek Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Cytek Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytek Biosciences are expected to grow in the coming year, from ($0.28) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytek Biosciences is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytek Biosciences is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytek Biosciences has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.50% of the float of Cytek Biosciences has been sold short.Short Interest Ratio / Days to CoverCytek Biosciences has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cytek Biosciences has recently decreased by 6.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytek Biosciences does not currently pay a dividend.Dividend GrowthCytek Biosciences does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.27 News SentimentCytek Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytek Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders10.36% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cytek Biosciences' insider trading history. Receive CTKB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTKB Stock News HeadlinesCytek Biosciences to Participate in Upcoming Investor ConferencesNovember 18 at 4:30 PM | globenewswire.comCytek Biosciences (CTKB) & Its Rivals Financial ReviewNovember 13, 2026 | americanbankingnews.comA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.November 20 at 1:00 AM | Concord Gold Capital (Ad)Cytek Biosciences, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 9, 2026 | seekingalpha.comCytek Aurora® Evo System Wins BioTech Breakthrough Award for Drug Discovery Innovation of the YearNovember 5, 2026 | globenewswire.comCytek outlines $208M-$211M 2026 revenue range while postponing business unit rollout to 2027November 5, 2026 | seekingalpha.comCytek Biosciences (CTKB) Q3 2026 Earnings Call TranscriptNovember 5, 2026 | finance.yahoo.comCytek Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 4, 2026 | marketscreener.comMSee More Headlines CTKB Stock Analysis - Frequently Asked Questions How have CTKB shares performed this year? Cytek Biosciences' stock was trading at $5.05 at the start of the year. Since then, CTKB shares have increased by 21.3% and is now trading at $6.1250. How were Cytek Biosciences' earnings last quarter? Cytek Biosciences, Inc. (NASDAQ:CTKB) issued its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The business had revenue of $53.23 million for the quarter, compared to analyst estimates of $53.05 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 13.13% and a negative net margin of 39.10%. Read the conference call transcript. How will Cytek Biosciences' stock buyback program work? Cytek Biosciences' Board of Directors approved a stock repurchase plan on Monday, December 30th 2024, which allows the company to repurchase $50 million in outstanding shares, according to EventVestor. This means that the company could reacquire up to 5.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its stock is undervalued. When did Cytek Biosciences IPO? Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Thursday, July 22nd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share. Who are Cytek Biosciences' major shareholders? Cytek Biosciences' top institutional shareholders include Boston Partners (4.99%), State Street Corp (1.95%), Russell Investments Group Ltd. (1.87%) and Goldman Sachs Group Inc. (1.78%). Insiders that own company stock include Ming Yan, Patrik Jeanmonod and William D Mccombe. View institutional ownership trends. How do I buy shares of Cytek Biosciences? Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytek Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include Micron Technology (MU), SoFi Technologies (SOFI), Kinross Gold (KGC), UiPath (PATH), Taiwan Semiconductor Manufacturing (TSM), Palantir Technologies (PLTR) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/04/2026Today11/20/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CTKB's financial health is in the Green zone, according to TradeSmith. CTKB has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CTKB CIK1831915 Webwww.cytekbio.com Phone877-922-9835FaxN/AEmployees703Year Founded1992Price Target and Rating Average Price Target for Cytek Biosciences$5.67 High Price Target$7.00 Low Price Target$5.00 Potential Upside/Downside-7.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.54 million Net Margins-39.10% Pretax Margin-19.24% Return on Equity-13.13% Return on Assets-9.56% Debt Debt-to-Equity RatioN/A Current Ratio4.46 Quick Ratio3.84 Sales & Book Value Annual Sales$201.49 million Price / Sales3.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book2.48Miscellaneous Outstanding Shares130,780,000Free Float117,235,000Market Cap$798.54 million OptionableOptionable Beta1.15 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:CTKB) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.